Please look at the link at the bottom of this page

http://oralcancerfoundation.org/treatment/targeted_therapies.htm

Also it is well documented, and in a recently posted news story on the OCF news site, that the rash response to Erbitux, is, while discomforting, a positive sign that the treatment is effective. In peer reviewed studies, those that had acute response in the form of a rash, also had the greatest success rates with the treatment.

Brian, stage 4 oral cancer survivor. OCF Founder and Director. The first responsibility of a leader is to define reality. The last is to say thank you. In between, the leader is a servant.